Engineered Treg cells as putative therapeutics against inflammatory diseases and beyond

Trends Immunol. 2023 Jun;44(6):468-483. doi: 10.1016/j.it.2023.04.005. Epub 2023 Apr 25.

Abstract

Regulatory T (Treg) cells ensure tolerance against self-antigens, limit excessive inflammation, and support tissue repair processes. Therefore, Treg cells are currently attractive candidates for the treatment of certain inflammatory diseases, autoimmune disorders, or transplant rejection. Early clinical trials have proved the safety and efficacy of certain Treg cell therapies in inflammatory diseases. We summarize recent advances in engineering Treg cells, including the concept of biosensors for inflammation. We assess Treg cell engineering possibilities for novel functional units, including Treg cell modifications influencing stability, migration, and tissue adaptation. Finally, we outline perspectives of engineered Treg cells going beyond inflammatory diseases by using custom-designed receptors and read-out systems, aiming to use Treg cells as in vivo diagnostic tools and drug delivery vehicles.

Keywords: CARs; Treg cells; autoimmunity; engineering of Treg cells; inflammation; regulatory T cells; synthetic immunology; transplantation.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autoimmune Diseases* / therapy
  • Humans
  • Immune Tolerance
  • Immunotherapy, Adoptive
  • Inflammation / therapy
  • T-Lymphocytes, Regulatory*